Literature DB >> 10223217

Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990.

E T van den Bergh1, M H Gasem, M Keuter, M V Dolmans.   

Abstract

The outcome in three groups of patients with bacteriologically confirmed typhoid fever caused by Salmonella typhi, treated during three episodes between 1948 and 1990 in Java, Indonesia, was compared by retrospective analysis of hospital records. The study population consisted of three groups of patients. Group I (n = 50) was treated in Batavia (the present Jakarta) from 1948 to 1950, Group II (n = 61) in Yogyakarta from 1952 to 1956, Group III (n = 105) in Semarang from 1989 to 1990. Main outcome measures were days until defervescence, early relapses during hospitalization, duration of hospital stay, complications and mortality. Group I received supportive treatment only, Group II low doses of chloramphenicol (total 12.5 g) and Group III full doses of chloramphenicol (total 27 g); occasionally other antibiotics were used. In Group I, II and III the mean number of days until defervescence was 16, 8 and 6 and the mean number of days in hospital 43, 47 and 15, respectively. Mortality was 26%, 10% and 5% and complications occurred in 38%, 18% and 13%, respectively. Between Group I and Group II the differences in mortality and complications were statistically significant (P < 0.05). Compared to Group I the proportion of early relapses was higher in Group II, but was zero in Group III. There were significantly fewer gastrointestinal complications in Group II than in Group I (P < 0.01) and even fewer in Group III. When no antibiotic against S. typhi was available, typhoid fever had a protracted course, and only 74% of patients survived. Even with low dosages of chloramphenicol, defervescence was earlier and mortality and complications decreased dramatically, but early relapses were frequent. Full doses of chloramphenicol for a sufficient period of time only slightly reduced mortality and complications further, but eliminated early relapses completely.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223217     DOI: 10.1046/j.1365-3156.1999.43374.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  16 in total

1.  Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.

Authors:  M Hussein Gasem; Monique Keuter; Wil M V Dolmans; Johanna Van Der Ven-Jongekrijg; Robert Djokomoeljanto; Jos W M Van Der Meer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Current concepts in the diagnosis and treatment of typhoid fever.

Authors:  Zulfiqar A Bhutta
Journal:  BMJ       Date:  2006-07-08

3.  Variation at HLA-DRB1 is associated with resistance to enteric fever.

Authors:  Sarah J Dunstan; Nguyen Thi Hue; Buhm Han; Zheng Li; Trinh Thi Bich Tram; Kar Seng Sim; Christopher M Parry; Nguyen Tran Chinh; Ha Vinh; Nguyen Phu Huong Lan; Nga Tran Vu Thieu; Phat Voong Vinh; Samir Koirala; Sabina Dongol; Amit Arjyal; Abhilasha Karkey; Olita Shilpakar; Christiane Dolecek; Jia Nee Foo; Le Thi Phuong; Mai Ngoc Lanh; Tan Do; Tin Aung; Do Nu Hon; Yik Ying Teo; Martin L Hibberd; Katherine L Anders; Yukinori Okada; Soumya Raychaudhuri; Cameron P Simmons; Stephen Baker; Paul I W de Bakker; Buddha Basnyat; Tran Tinh Hien; Jeremy J Farrar; Chiea Chuen Khor
Journal:  Nat Genet       Date:  2014-11-10       Impact factor: 38.330

Review 4.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

5.  Extensively Drug-Resistant Typhoid Fever in the United States.

Authors:  Michael J Hughes; Meseret G Birhane; Layne Dorough; Jared L Reynolds; Hayat Caidi; Kaitlin A Tagg; Caroline M Snyder; Alexander T Yu; Shana M Altman; Michelle M Boyle; Deepam Thomas; Amy E Robbins; HaeNa A Waechter; Irina Cody; Eric D Mintz; Bruce Gutelius; Gayle Langley; Louise K Francois Watkins
Journal:  Open Forum Infect Dis       Date:  2021-11-16       Impact factor: 3.835

6.  Characteristics and risk factors for typhoid fever after the tsunami, earthquake and under normal conditions in Indonesia.

Authors:  Agung Budi Sutiono; Andri Qiantori; Hirohiko Suwa; Toshizumi Ohta
Journal:  BMC Res Notes       Date:  2010-04-17

7.  Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study.

Authors:  John A Crump; Katrina Kretsinger; Kathryn Gay; R Michael Hoekstra; Duc J Vugia; Sharon Hurd; Susan D Segler; Melanie Megginson; L Jeffrey Luedeman; Beletshachew Shiferaw; Samir S Hanna; Kevin W Joyce; Eric D Mintz; Frederick J Angulo
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 8.  Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.

Authors:  J A Crump; P K Ram; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

9.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

10.  Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.

Authors:  Tamilarasu Kadhiravan; Naveet Wig; Arti Kapil; S K Kabra; K Renuka; Anoop Misra
Journal:  BMC Infect Dis       Date:  2005-05-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.